All In Biotech

Drug Trial Radar · NCT06522997

A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

A Phase 2b Dose-finding, Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of BAY 3283142 on Top of Standard of Care in Reducing Albuminuria in Patients With Chronic Kidney Disease

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,222 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,222

Actual

Start

Aug 8, 2024

Primary completion

Oct 24, 2025

Study completion Nov 20, 2025

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jul 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), CKD is a condition in which the kidneys' ability to work properly gradually decreases over time. A common sign of decreasing kidney function is the body losing too much of a protein called albumin in the urine. This condition is known as albuminuria. This can lead to a faster decline in kidney function. People who have high blood pressure and diabetes are more likely to have CKD and are at a higher risk of complications related to it. BAY3283142 is a new drug that is being developed to treat people with CKD. It works by activating a protein that helps relax blood vessels and is thought to have beneficial effects in CKD. In this study, researchers want to learn about how well different doses of BAY3283142 work when taken with standard treatment for CKD in reducing albumin in the urine of participants with CKD. They will compare the results of the change in the urine albumin-creatinine ratio (UACR) after 16 weeks for BAY3283142 with a placebo. A placebo looks like the study drug but does not have any medicine in it. During the study, participants will take either of the following drugs: * BAY3283142: Participants will take BAY3283142 as tablets by mouth. * Placebo: Participants will take it in the same way as BAY3283142. Participants will continue taking the available standard treatment for CKD and other conditions they may have (for example, heart conditions and diabetes). At the start of this study, the researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the participants. Researchers will take urine and blood samples from the participants at different time points to measure UACR and eGFR. Participants will be divided equally into different groups. Only 1 group will receive placebo and the other groups will receive BAY3283142. Participants will take their assigned treatment for 16 weeks. No one will know who receives which drug or dose of BAY3283142 during the study. Participants will be in this study for around 23 weeks. This includes the time for screening before the start of treatment and follow-up with participants after treatment. People can join this study if they: * are 18 years of age or older and have been diagnosed with CKD * have poor kidney function according to the eGFR test * have abnormally high levels of albumin in the urine according to the UACR test * have been taking certain drugs at a stable dose for management of high blood pressure, diabetes, kidney disease, etc. for at least 4 weeks before the start of the study People cannot join this study if they: * have low blood pressure * have had a stroke or a heart attack, or were hospitalized because of heart failure in the 3 months before the start of the study * have a serious liver disease * have a kidney disease for which they need to take drugs that control the immune system The detailed requirements will be discussed between the study doctors and people considering joining this study. Participants may or may not get the expected benefits of treatment with BAY3283142, but they will receive thorough medical check-ups during this study. These can help to improve individual treatment in the future and to identify unknown medical risks. Some participants may experience medical problems during this study including pain and discomfort when blood samples are taken. Researchers will closely monitor and manage any medical problems the participants may have. They will not include people who should not take BAY3283142 due to known safety concerns. The findings from this study may contribute to developing a new treatment option for people with CKD who have excess albumin in the urine.

Conditions

  • Chronic Kidney Disease

Interventions

  • BAY3283142Drug

    Tablet, intake orally once daily

  • PlaceboDrug

    Matching with BAY3283142

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to Week 16 in the logarithm of urine albumin-creatinine ratio (UACR)Time frame: From baseline to Week 16

Locations

153 sites in 15 countries. Site status is shown where the registry gives one.

  • Nephrology Consultants, LLC

    Huntsville, Alabama

  • Balboa Research SMO+ - Chula Vista

    Chula Vista, California

  • California Kidney Specialists - San Dimas

    San Dimas, California

  • Yale Nephrology Clinical Research Clinic

    New Haven, Connecticut

  • Nova Clinical Research - Blake Medical Center

    Bradenton, Florida

  • Renstar Medical Research - Deerwood Clinic

    Ocala, Florida

  • Elixia Central Florida

    Orlando, Florida

  • Florida Institue for Clinical Research

    Orlando, Florida

  • Southeastern Clinical Research Institute, LLC

    Augusta, Georgia

  • Research by Design, LLC | Chicago, IL

    Chicago, Illinois

  • Nephrology Associates of Northern Illinois and Indiana - Hinsdale

    Hinsdale, Illinois

  • Triad Internal Medicine - Asheboro

    Asheboro, North Carolina

  • Eastern Nephrology Associates - New Bern

    New Bern, North Carolina

  • Brookview Hills Research Associates, LLC

    Winston-Salem, North Carolina

  • Knoxville Kidney Center, PLLC

    Knoxville, Tennessee

  • Vanderbilt University Medical Center - Nephrology Clinical Trials Center

    Nashville, Tennessee

  • Renal Disease Research Institute | Landry

    Dallas, Texas

  • Southwest Houston Research, Ltd.

    Houston, Texas

  • Clinical Advancement Center, PLLC

    San Antonio, Texas

  • Utah Kidney Research Institute | Salt Lake City, UT

    South Salt Lake, Utah

  • Peninsula Kidney Associates - Hampton

    Hampton, Virginia

  • Manassas Clinical Research Center

    Manassas, Virginia

  • Salem VA Medical Center - Nephrology

    Salem, Virginia

  • Mendez Center For Clinical Research | Woodbridge, VA

    Woodbridge, Virginia

  • Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC)

    Buenos Aires, Argentina

  • Centro Privado San Vicente Diabetes

    Córdoba, Argentina

  • Fundacion Centro de Salud e Investigaciones Medicas | Santa Rosa, Argentina

    Santa Rosa, Argentina

  • Centro de Investigaciones Metabolicas | Ciudad de Autonoma de Buenos Aires, Argentina

    Ciudad Autónoma de Buenos Aire, Buenos Aires, Argentina

  • Centro de Investigaciones Medicas Temperley | Buenos Aires, Argentina

    Temperley, Buenos Aires, Argentina

  • CEDIC Centro de Investigación Clínica | Buenos Aires, Argentina

    CABA, Ciudad Auton. de Buenos Aires, Argentina

  • Centro de Especialidades Medicas (Cemedic) | Cardiology Department

    Villa Luro, Ciudad Auton. de Buenos Aires, Argentina

  • Centro de Rehabilitacion Cardiovascular | San Luis, Argentina

    San Luis, San Luis Province, Argentina

  • Epicura / Nephrology

    Baudour, Belgium

  • UZ Gent / Nephrology

    Ghent, Belgium

  • Jan Yperman Ziekenhuis / Nephrology

    Ieper, Belgium

  • UZ Brussel Nephrology

    Jette, Belgium

  • UZ Leuven / Nephrology

    Leuven, Belgium

  • AZ Delta / Nephrology

    Roeselare, Belgium

  • Capital Medical University (CMU) - Beijing Anzhen Hospital (BAH)

    Beijing, China

  • Peking University People's Hospital

    Beijing, China

Showing 40 of 153 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.